The Annals Visit the PharmaCE website!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

Drug Intelligence & Clinical Pharmacy: Vol. 20, No. 6, pp. 487-489.
© 1986 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krummel, S.
Right arrow Articles by Wesner, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krummel, S.
Right arrow Articles by Wesner, R.

Research Articles

Exacerbation of acute intermittent porphyria by nortriptyline

SJ Krummel and RB Wesner

Many medications have been reported to produce attacks of acute intermittent porphyria (AIP). Nortriptyline has been reported to be safe in porphyric patients. We present a case of AIP exacerbated by nortriptyline.


This article has been cited by other articles:


Home page
 J PsychopharmacolHome page
S. B. Dover, A. Graham, M. R. Moore, and K. E. L. McColl
Lofepramine--a safe anti-depressant in acute hepatic porphyria?
J Psychopharmacol, January 1, 1994; 8(2): 104 - 108.
[Abstract] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 1986 by Harvey Whitney Books Company.